Migraine Drugs Market 2024 – Market Size & Segments Analysis, Industry Trends, Manufacturers Analysis, Opportunities and Forecast 2034

Migraine a common and deliberating neurological disorder characterized by intense, recurring headaches, often accompanied by nausea, vomiting, and sensitivity to light and sound. The symptoms of migraine which affect children and teenagers as well as adults, can progress through four stages: prodrome, aura, attack and post-drome. The management of migraine involves both acute abortive and preventive/prophylactic treatments. The drugs are consumed both orally and injected for the treatment.

MARKET OVERVIEW

The market valuation of migraine drugs market was valued at approximately USD 4.9 billion in 2023 and is projected to reach USD 7.6 billion in 2034 exhibiting a CAGR of 4.4% during the forecast period of 2024-2034. Migraine drugs offer a range of treatment options tailored to the needs of patients. The market is aligned with healthcare sector, which makes it a sustainable and growing market.

GROWTH DRIVERS

 The rising incidence of migraine is the significant driver of the market, which increases the demand of the effective treatment. According to a JAMA Network article, the incidence of migraines increased by 56% in women and 34% in men overall. The highest rate of increase was in women aged 20–29, from 600 to 1,000 new cases per 100,000 women per year. According to NCBI, the global prevalence of migraines increased by 1.7% from 1990 to 2019, with an estimated 1.1 billion cases in 2019. The highest growth in incidence was seen in males and people aged 10–14, while prevalence and DALYs were highest in females and people aged 20–24. East Asia saw the fastest increase in incidence, and Tropical Latin America saw the fastest increase in prevalence and DALYs.

South Asia had the highest prevalence of migraines in 2019, with an estimated 154,490,169.8 cases. The advances in the understanding of the pathophysiology of migraines leads to the development of more targeted therapies like CGRP inhibitor which is one of the significant drivers of the market. The increased awareness about migraines and improved diagnostic criteria leads to more patients seeking treatment. These educational campaigns the organizations like Migraine Trust, drives the adoption of the markets. The expansion of healthcare infrastructure in emerging economies, it allows for greater access to advanced treatment. This expansion is significant driver of the market.

According to Becker and WHO, the cost of global healthcare soared from 7.4% in 2022 to 10.7% in 2023, a record high. The 2024 insurer-reported cost trend is forecasted at 9.9% average worldwide, though some regions will see a steeper increase. There is a sharp increase in government spending on health at all country income levels underpinned the rise in health spending to a new high of USD 9 trillion, which is approximately 11% of global GDP. The modern lifestyle changes with increased stress and screen time have contributed to a rise in migraine incidence, which demands for effective treatment.

According to NIH, pre pandemic mean educational screen time was 0.5 (1.2) hours per day and increased 0.93 hours per day (95%) in the first pandemic period and 0.46 hours per day in the second pandemic period. According to another report, the average amount of time people spend on internet-connected screens has increased by 13% since 2013, from 6 hours and 9 minutes in 2013 to 6 hours and 58 minutes in 2023. This equates to more than 5 billion extra days of screen time for all internet users worldwide.

MARKET SEGMENTATION:

·         By Type- Acute/Abortive Treatment (Analgesic, Ergotamine, Triptans), Preventive/P Treatment (Beta Blockers, Anti-serotonergic drugs, anti-depressants, anticonvulsants, calcium channel blockers)

·         By Route of Administration- Oral, Injectable (Pre-filled Syringes, Vial)

·         By Distribution Channel- hospital pharmacies, retail pharmacies and online pharmacies

·         By Region- North America, Europe, Asia Pacific, The Middle East and Africa, South America

Migraine Drugs Market Segment By Type Review:

The migraine drugs market is segmented by type into two primary categories, including acute/abortive and preventive prophylactic treatment. The acute/abortive treatments are designed to relieve the symptoms of a migraine attack once it begins. These treatments are taken during the onset of a migraine to reduce severity and duration. The analgesics includes nonprescription medications like aspirin, ibuprofen, acetaminophen and other combination drugs. These drugs work by inhibiting pain pathways and reducing inflammation. The ergotamine constricts blood vessels in the brain and reduces the inflammation. The triptans are considered to be a gold standard for acute migraine treatment.

The preventive treatments are taken regularly to reduce the frequency, severity and duration of migraine attacks. These treatments are recommended for patients with frequent or severe migraine that significantly impact quality of life. The beta blockers reduces the excitability of neurons and stabilizes the blood vessel. The anti-serotonergic drugs block serotonin receptors to prevent vasodilation and inflammation. The antidepressants modulate neurotransmitters involved in migraine pathophysiology. The anti-convulsant stabilizes neural membranes and inhibits repetitive neuronal firing. The calcium channel blockers inhibits calcium influx in the neurons, which stabilizes the vascular tone.

Migraine Drugs Market Segment By Route of Administration Review:

The oral administration is one of the most common and preferred routes for migraine medication, due to its convenience and ease of use. This route includes tablets, capsules, and liquid formulations. The injectable migraine medications provide a rapid onset of action and are particularly useful for severe or refractory migraines. This route includes prefilled syringes and vials. The prefilled syringes includes sumatriptan injections and CGRP inhibitors. It is directly administrated into the bloodstream or subcutaneous tissue. It provides rapid relief by bypassing gastrointestinal absorption. the vials include dihydroergotamine mesylate and certain other ergot alkaloids. It is administrated intramuscularly often in a clinical setting for a rapid effect.

Migraine Drugs Market Segment By Distribution Channel Review:

The hospital pharmacies are an integral part of the healthcare system, providing medications to inpatients and outpatients. They ensure that patients receive the correct medication with appropriate instructions directly from the healthcare facility. The hospital pharmacy is worked closely with doctors and nurses, ensuring that prescriptions are accurately filled and tailored to patient needs. The retail pharmacies, including large chains and independent pharmacies, are the most common and accessible points for purchasing medications.

They offer a wide range of over the counter and prescription drugs. he retails pharmacies are widely distributed in urban and rural areas, providing easy access for most patients. Many retail pharmacies have extended hours, including 24/7 operations in some locations. The online pharmacies have grown significantly in recent, offering patients the ability to order medications from the comfort of their homes. They provide prescription and OTC medications through digital platforms. Online pharmacies often have an extensive inventory, including hard to find medications.

Migraine Drugs Market Regional Analysis:

North America is a significant market driven by high prevalence and awareness of migraine. The American Migraine Foundation (AMF) estimates that at least 39 million Americans live with migraines, which is about one in four households in the US. The region has a robust and well-established healthcare infrastructure that supports the widespread of adoption of the market. Europe is a valuable market driven by the the government support and funding like European union funding for neurological disorders include migraines, which drives the market towards growth.

Asia Pacific is a rapid growing market driven by rising healthcare expenditure in countries like China and India, that allows for greater access to advanced migraine treatments. The Middle East and Africa is a promising it driven by investments in healthcare infrastructure in several Middle East and African countries. South America is a growing market driven by increasing access to healthcare and growing pharmaceutical market.

Key Challenges:

The advance migraine treatments, particularly new medications like CGRP inhibitors, may be very expensive, which makes them inaccessible to many patients. The limited insurance coverage for new and expensive treatments may further restrict the patient access. According to WebMD,  costs may vary around the country, the average cost for one visit is USD 130 to USD 180 for an adult without insurance, or around a USD 30 copay if you are insured. Your doctor may refer you instead to a specialist called a neurologist for diagnosis. Online, neurologist office visits are typically priced at USD 200 to USD 400 before insurance. Moreover there as tests including blood tests, MRI scans, CT scans, EEG and more.

Competitive Landscape:

In the highly competitive Migraine Drugs market, companies are investing heavily in research and development to innovate and improve the product and services. They are also collaborating, forming strategi partnerships, or acquiring other companies to gain access to new market segments, enhance distribution networks, and increase market share. Recent developments includes – BioDelivery Sciences received approval from the Food and Drug Administration for Elyxyb, in January 2022. Biohaven Pharmaceutical and Pfizer revealed positive top-line results with a Phase 3 clinical trial. It was for Rimegepant, a tiny molecule targeting calcitonin gene-related peptide (CGRP) receptors, in February 2022. Tonix's TNX-102 SL under phase 3 development, in December 2023.

Global Key Players:

·         Novartis AG

·         AstraZeneca

·         Amgen Inc.

·         Abbvie

·         Glaxo SmithKline plc

·         Eli Lilly and Compnany

·         Abbott Laboratories

·         Teva Pharmaceuticals Industries

·         Pfizer

·         Merck & Co. Inc

·         Bausch Health Companies

·         Janssen Pharmaceutical Company

·         Biohaven Pharmaceutical Holding Company

·         Endo Pharmaceutical

·         Other Players

Attributes	Details
Base Year	2023
Trend Period	2024 – 2034
Forecast Period	2024 – 2034
Pages	215
By Type	Acute/Abortive Treatment (Analgesic, Ergotamine, Triptans), Preventive/Prophylactic Treatment (Beta Blockers, Anti-serotonergic drugs, anti-depressants, anticonvulsants, calcium channel blockers)
By Route of Administration	Oral, Injectable (Pre-filled Syringes, Vial)
By Distribution Channel	hospital pharmacies, retail pharmacies and online pharmacies
By region	North America, Europe, Asia Pacific, the Middle East and Africa, and South America
Company Profiles	Novartis AG, AstraZeneca, Amgen Inc., Abbvie, Glaxo SmithKline plc, Eli Lilly and Compnany, Abbott Laboratories, Teva Pharmaceuticals Industries, Pfizer, Merck & Co. Inc, Bausch Health Companies, Janssen Pharmaceutical Company, Biohaven Pharmaceutical Holding Company, Endo Pharmaceutical, Other Players
Edition	1st edition
Publication	June 2024